Avalo Therapeutics AVTX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$19.63M-49.3% | -$13.72M+61.2% | -$30.63M-233% | -$20.77M-121% | -$13.15M+89.2% | ||
| $17K-87.4% | $16K-76.5% | $59K+73.5% | $134K+306% | $135K+297% | ||
| $3.58M+10.3% | $4.51M+55.2% | $3.15M+70.7% | $2.72M+477% | $3.24M+415% | ||
| -$17.69M-87.1% | -$14.25M+5.3% | -$16.37M-42.0% | -$11.39M+30.0% | -$9.46M-52.5% | ||
| $25.51M— | $0— | -$13.26M— | -$70.86M— | $0-100% | ||
| $1.4M— | $687K-99.0% | $14.37M— | -$469K— | $0-100% | ||
| $9.21M+197% | -$11.16M-121% | -$15.26M— | -$82.72M— | -$9.46M-109% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Avalo Therapeutics generate?
- Avalo Therapeutics (AVTX) generated -$59.7M in operating cash flow over the trailing twelve months.
- Where does Avalo Therapeutics's cash flow data come from?
- Every line is extracted from Avalo Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.